✦ LIBER ✦

Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis

✍ Scribed by Calleja, Jose L.; Pascasio, Juan M.; Ruiz-Antorán, Belén; Gea, Francisco; Bárcena, Rafael; Larrubia, Juan R.; Pérez-Álvarez, Ramón; Sousa, Jose M.; Romero-Gómez, Manuel; Solá, Ricard; de la Revilla, Juan; Crespo, Javier; Navarro, Jose M.; Arenas, Juan I.; Delgado, Manuel; Fernández-Rodríguez, Conrado M.; Planas, Ramon; Buti, Maria; Forns, Xavier

Book ID: 125853257
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 427 KB
Volume: 35
Category: Article
ISSN: 0106-9543
DOI: 10.1111/liv.12656

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

799 EFFICACY AND SAFETY OF TRIPLE-THERAP

799 EFFICACY AND SAFETY OF TRIPLE-THERAPY WITH PEGINTERFERON-RIBAVIRIN, AND BOCEPREVIR AS COMPASSIONATE-USE IN SPANISH PATIENTS WITH HEPATITIS C GENOTYPE 1 WITH SEVERE FIBROSIS: INTERIM-ANALYSIS AT 12 WEEKS

✍ Calleja, J.L.; Pascasio, J.M.; Ruiz-Antoran, B.; Larrubia, J.R.; Gea, F.; de la 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 129 KB

P1158 EFFICACY AND SAFETY OF BOCEPREVIR-

P1158 EFFICACY AND SAFETY OF BOCEPREVIR-BASED THERAPY IN HCVG1 TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS: THE ITALIAN AND SPANISH NPP EARLY ACCESS PROGRAM

✍ Bruno, S.; Bollani, S.; Pascasio, J.M.; Zignego, A.L.; Di Marco, V.; Magni, C.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 58 KB

601 EFFICACY AND SAFETY OF PEGINTERFERON

601 EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 μG/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE 1 PATIENTS WITH CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY

✍ W.S.C. Cheng; S. Roberts; M. Weltman; D.H.G. Crawford; W. Sievert; G. McCaughan; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Efficacy of boceprevir, an NS3 protease

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

✍ Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; Da 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 378 KB

Sa1051 Boceprevir Based Triple Therapy i

Sa1051 Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment NaïVE Patients Infected With Chronic Hepatitis C, Genotype 1: An Interim Analysis At Week 12 After Start of Treatment

✍ Moog, Gero; Mauss, Stefan; Hueppe, Dietrich; Spengler, Ulrich; Schott, Eckart; E 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 646 KB

187 Efficacy and safety of 22 weeks of m

187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial

✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB